AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30830974
Drug: MDT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT treatment allocation where resectability assessments were concordant
Trial: 29158678
Drug: DFN-15 120
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-15 120 mg
Trial: 28748412
Drug: DFN-15 180
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-15 180 mg
Trial: 29158678
Drug: DFN-15 240
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-15 240 mg
Trial: 23417765
Drug: Blonanserin under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blonanserin under fasting (single dose 4, 8, and 12 mg)
Trial: 23417765
Drug: Blonanserin under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blonanserin under food intake (single dose 8 mg)
Trial: 21236333
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500mg twice per day)
Trial: 18783388
Drug: On-demand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand treatment with esomeprazole 20 mg
Trial: 18783388
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with esomeprazole 20 mg once a day
Trial: 11713439
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (0.3 mg/kg/wk)
Trial: 8422091
Drug: Growth hormone-releasing
RxNorm normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Growth hormone-releasing factor (GH-RF)
Trial: 3630291
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase short-term lysis
Trial: 3630291
Drug: Conventional heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional heparin phenprocoumon treatment
Trial: 30753101
Drug: SynGEM (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SynGEM (both doses)
Trial: 8603242
Drug: Human corticotropin-releasing
RxNorm normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human corticotropin-releasing factor (hCRF) at doses of 2, 4, and 8 mu g/kg body weight
Trial: 8603242
Drug: Human corticotropin-releasing
RxNorm normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human corticotropin-releasing factor (hCRF) at 8 mu g/kg
Trial: 30076800
Drug: REMOTE-CR (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REMOTE-CR (12 weeks of individualized exercise prescription, real-time physiological monitoring, coaching, and behavioral support)
Trial: 19357525
Drug: L-acetylcarnitine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetylcarnitine + BCAA
Trial: 16872787
Drug: Tailored intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored intervention with booster dose
Trial: 16872787
Drug: Tailored intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored intervention without booster dose
Trial: 15159241
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (4.5 g/d during the first 4 months of lactation)
Trial: 15159241
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein intake (measured as g/d)
Trial: 16552194
Drug: Intergel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intergel treatment (0.5% ferric hyaluronate gel)
Trial: 16552194
Drug: Intergel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intergel treatment
Trial: 29655061
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone
Trial: 3550556
Drug: Concomitant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy and endocrine therapy
Trial: 27613076
Drug: DFN-02 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-02 (10 mg sumatriptan plus 0.20% DDM)
Trial: 1333181
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg subcutaneous sumatriptan
Trial: 17221340
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg subcutaneous sumatriptan
Trial: 15663589
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day oral tibolone
Trial: 2265045
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg‐1
Trial: 2787664
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg kg‐1
Trial: 3519225
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose furosemide (120 mg i.v. during the initial 24 hours)
Trial: 3519225
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose furosemide (20 mg i.v. during the initial 24 hours)
Trial: 27130973
Drug: Conventional anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional anti-VEGF therapy
Trial: 24351072
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of myo-inositol/die plus 400 mcg of folic acid/die orally for six months
Trial: 19523875
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (1000 mg/day for 12 weeks)
Trial: 15831642
Drug: Cardiac Resynchronisation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronisation Therapy (CRT)
Trial: 14568269
Drug: 9 mcg
RxNorm normalized name: Nasarel, 29 mcg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mcg of consensus interferon plus ribavirin (1000/1200 mg/daily) for 24 weeks (group A)
Trial: 14568269
Drug: 18 mcg
RxNorm normalized name: Spiriva, 18 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mcg of consensus interferon plus ribavirin (1000/1200 mg/daily) for 24 weeks (group B)
Trial: 14568269
Drug: 9 mcg
RxNorm normalized name: Nasarel, 29 mcg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mcg of consensus interferon plus ribavirin for 48 weeks (group C)
Trial: 14568269
Drug: 18 mcg
RxNorm normalized name: Spiriva, 18 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mcg of consensus interferon plus ribavirin for 48 weeks (group D)
Trial: 14568269
Drug: 9 mcg
RxNorm normalized name: Nasarel, 29 mcg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mcg of consensus interferon plus ribavirin for 48 weeks in naive genotype 1 patients
Trial: 8982555
Drug: 1α-hydroxycalciferol (1α[OH]D3)
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1α-hydroxycalciferol (1α[OH]D3) at a low dose (0.25 μg/day, n = 56, Group L)
Trial: 8982555
Drug: 1α-hydroxycalciferol (1α[OH]D3)
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1α-hydroxycalciferol (1α[OH]D3) at a higher dose (0.5 to 1.0 μg/day, average 0.58 ± 0.02 μg/day, n = 65, Group H)
Trial: 8982555
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 44, Group N)
Trial: 1680275
Drug: Dimethindene maleate
RxNorm normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethindene maleate (4 mg)
Trial: 15715190
Drug: Oral temazepam
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral temazepam plus nebulised Lignocaine
Trial: 15715190
Drug: Intravenous alfentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfentanyl
Trial: 10233322
Drug: Borage oil
RxNorm normalized name: Borage oil
DrugBank: Borage oil (DB11238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Borage oil (500 mg daily)
Trial: 7595759
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) 2 mg/m2/d, days 1, 2; Etoposide 200-300 mg/m2/d, days 1-3; G-CSF 5-10 micrograms/d subcutaneously, days 4-18, every 4 weeks
Trial: 7595759
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) and Etoposide with G-CSF
Trial: 7761011
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (0.4 mg)
Trial: 24225081
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation (20 grams twice a day)
Trial: 21273606
Drug: Saracatinib (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib (175 mg daily, orally or via gastrostomy tube)
Trial: 19470385
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg rapamycin
Trial: 19470385
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg rapamycin
Trial: 17943687
Drug: Neurocognitive enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocognitive enhancement therapy (NET) + Work therapy (WT)
Trial: 11483228
Drug: Extend Bar
RxNorm normalized name: Medicated Bar Soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extend Bar (30 g total carbohydrate, including 5 g uncooked cornstarch, 3 g protein, 3 g fat)
Trial: 11483228
Drug: Placebo Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Bar (30 g total carbohydrate, 3 g protein, 3 g fat)
Trial: 9489591
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg orally) with food
Trial: 9489591
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg orally) after food
Trial: 9489591
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg orally) fasting
Trial: 29316885
Drug: Monthly cash
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly cash transfer (unconditional)
Trial: 28843616
Drug: Pirfenidone (2.403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (2.403 mg/daily) for one year
Trial: 7639372
Drug: methohexital (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methohexital (0.5 mg/kg)
Trial: 12389657
Drug: Closure of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closure of subcutaneous fat layer with a running 3‐0 plain suture
Trial: 10429836
Drug: Zanamivir 4
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir 4 mg intravenously in healthy participants and those with mild/moderate renal impairment
Trial: 8538187
Drug: 4-HPR at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-HPR at a dose of 200 mg po for one year in basal cell carcinoma study
Trial: 2147161
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (100 mg)
Trial: 2147161
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medroxyprogesterone acetate and tamoxifen (2 x 10 mg)
Trial: 28430384
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone 8 mg/0.4 ml
Trial: 28430384
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone 16 mg/0.4 ml
Trial: 28430384
Drug: Sublingual naloxone
RxNorm normalized name: buprenorphine / naloxone Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual naloxone 16 mg/ml
Trial: 26589371
Drug: Essential phospholipid
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential phospholipid (EPL) 1800 mg/day for 24 weeks, followed by 900 mg for 48 weeks
Trial: 24020649
Drug: Adenosine and
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine and Isoproterenol administration with no further ablation for non-PV foci that did not induce AF (group 1C).
Trial: 24020649
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group undergoing PVAI without drug challenge (group 2).
Trial: 21857276
Drug: Single sciatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single sciatic nerve block followed by saline infusion and continuous lumbar plexus block (group C, n = 19)
Trial: 19232032
Drug: S100 +
RxNorm normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S100 + M2000 (sitagliptin 50 mg b.i.d. + metformin 1000 mg b.i.d.)
Trial: 19232032
Drug: S100 +
RxNorm normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S100 + M1000 (sitagliptin 50 mg b.i.d. + metformin 500 mg b.i.d.)
Trial: 19232032
Drug: M1000 (metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M1000 (metformin 500 mg b.i.d.)
Trial: 19232032
Drug: S100 (sitagliptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S100 (sitagliptin 100 mg q.d.)
Trial: 19232032
Drug: PBO/M2000 (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO/M2000 (placebo switched to metformin 1000 mg b.i.d. at week 24)
Trial: 17515742
Drug: Naprapathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprapathic manual therapy (Index Group)
Trial: 11594926
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg remacemide hydrochloride
Trial: 11594926
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg remacemide hydrochloride
Trial: 9561428
Drug: Binge eating
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binge eating disorder treatment
Trial: 2644750
Drug: Indomethacin (25‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25‐50 mg bolus plus infusion, 5‐7.5 mg h‐1)
Trial: 26101038
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (physical therapy)
Trial: 23529989
Drug: Dunaliella bardawil
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dunaliella bardawil capsules
Trial: 23529989
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch powder capsules)
Trial: 9184370
Drug: Empirical prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical prescribing of antibiotics
Trial: 3283783
Drug: Amitriptyline (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (median dose 125 mg daily)
Trial: 23324599
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (VD) 1,000 IU daily for four months
Trial: 14603195
Drug: Miniaturized sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miniaturized sequential device (CECT group)
Trial: 14603195
Drug: Standard calf-length
RxNorm normalized name: thymus gland-calf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard calf-length sequential IPC device (SCD group)
Trial: 23536584
Drug: Lixisenatide morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide morning injection
Trial: 23536584
Drug: Lixisenatide evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide evening injection
Trial: 17240493
Drug: DTaP-HepB-IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-HepB-IPV vaccine coadministered with PCV and Hib
Trial: 17240493
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of DTaP, HepB, IPV, Hib, and PCV
Trial: 9305417
Drug: Haloperidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.5 or 1.0 mg)
Trial: 31919583
Drug: Quinoa biscuits
RxNorm normalized name: quinoa oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinoa biscuits (15 g daily for 4 weeks)
Trial: 30594190
Drug: Chronic pain
RxNorm normalized name: Aspirin 81 mg ORAL TABLET [Chronic Pain/Fever Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic pain self-management course (2.5-h weekly sessions for 6 weeks)
Trial: 30594190
Drug: Low-impact outdoor
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-impact outdoor physical activity (1-h weekly sessions for 6 weeks)
Trial: 27055527
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate monotherapy (1200 or 1600 mg once daily)
Trial: 20565345
Drug: High-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cholecalciferol 50,000 IU daily for 10 days
Trial: 20565345
Drug: Low-dose cholecalciferol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cholecalciferol 3000 IU daily for 30 days, followed by 1000 IU daily for 60 days
Trial: 8780337
Drug: 2.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)
Trial: 8780337
Drug: 7.7 g
RxNorm normalized name: somatropin 13 % (1 gram/7.7 gram) MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.7 g EPA + DHA/d
Trial: 1452381
Drug: Hydrochlorothiazide 6.25
RxNorm normalized name: hydrochlorothiazide 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 6.25 mg
Trial: 3881175
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose human leukocyte alpha-interferon (10 X 10(6) units/day for 28 days)
Trial: 27438995
Drug: Raloxifene hydrochloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride, 120 mg/d
Trial: 20713879
Drug: IMC‐A12 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMC‐A12 monotherapy (10 mg/kg IV every 2 weeks)
Trial: 20713879
Drug: IMC‐A12 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMC‐A12 plus cetuximab (10 mg/kg IMC-A12 and 500 mg/m2 cetuximab IV every 2 weeks)
Trial: 18413068
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 150 mg/day (days 3 to 7) + oral phytoestrogen (Cimicifuga racemosa) 120 mg/day (days 1 to 12)
Trial: 16190795
Drug: Extended-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release methylphenidate (ER-MPH) 20 mg
Trial: 16190795
Drug: OROS-methylphenidate (OROS-MPH)
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-methylphenidate (OROS-MPH) 36 mg
Trial: 2181701
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron 2 mg/kg/d until the age of 6 months
Trial: 2181701
Drug: Intramuscular iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iron dextran 100 mg between the ages of 6 and 8 weeks
Trial: 111279
Drug: LAAM (1-Alpha-acetylmethadol)
RxNorm normalized name: LAAM
DrugBank: Levacetylmethadol (DB01227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAAM (1-Alpha-acetylmethadol) administered every other day
Trial: 111279
Drug: Methadone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone administered every day
Trial: 25180869
Drug: High-dose terlipressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose terlipressin (1 mg/6-8 h, n=27)
Trial: 25180869
Drug: Low-dose terlipressin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose terlipressin (1 mg/12 h, n=29)